<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK24599" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK24599/" /><meta name="ncbi_pagename" content="ALK-Related Neuroblastic Tumor Susceptibility - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>ALK-Related Neuroblastic Tumor Susceptibility - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="ALK-Related Neuroblastic Tumor Susceptibility" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/01/17" /><meta name="citation_author" content="Emily G Greengard" /><meta name="citation_author" content="Julie R Park" /><meta name="citation_pmid" content="20301782" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK24599/" /><meta name="citation_keywords" content="Neuroblastoma" /><meta name="citation_keywords" content="Ganglioneuroblastoma" /><meta name="citation_keywords" content="Ganglioneuroma" /><meta name="citation_keywords" content="ALK tyrosine kinase receptor" /><meta name="citation_keywords" content="ALK" /><meta name="citation_keywords" content="ALK-Related Neuroblastic Tumor Susceptibility" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="ALK-Related Neuroblastic Tumor Susceptibility" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Emily G Greengard" /><meta name="DC.Contributor" content="Julie R Park" /><meta name="DC.Date" content="2019/01/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK24599/" /><meta name="description" content="ALK-related neuroblastic tumor susceptibility is characterized by increased risk for neuroblastic tumors including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Neuroblastoma is a more malignant tumor and ganglioneuroma a more benign tumor. Depending on the histologic findings, ganglioneuroblastoma can behave in a more aggressive fashion, like neuroblastoma, or in a benign fashion, like ganglioneuroma. Preliminary data from the ten reported families with ALK-related neuroblastic tumor susceptibility suggest an overall penetrance of approximately 57% with the risk for neuroblastic tumor development highest in infancy and decreasing by late childhood." /><meta name="og:title" content="ALK-Related Neuroblastic Tumor Susceptibility" /><meta name="og:type" content="book" /><meta name="og:description" content="ALK-related neuroblastic tumor susceptibility is characterized by increased risk for neuroblastic tumors including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Neuroblastoma is a more malignant tumor and ganglioneuroma a more benign tumor. Depending on the histologic findings, ganglioneuroblastoma can behave in a more aggressive fashion, like neuroblastoma, or in a benign fashion, like ganglioneuroma. Preliminary data from the ten reported families with ALK-related neuroblastic tumor susceptibility suggest an overall penetrance of approximately 57% with the risk for neuroblastic tumor development highest in infancy and decreasing by late childhood." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK24599/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/alk-nbs/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK24599/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DB332E041BA9100000000070D02C7.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK24599_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK24599_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ipa/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/iahsp/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK24599_"><span class="title" itemprop="name"><i>ALK</i>-Related Neuroblastic Tumor Susceptibility</span></h1><p class="contrib-group"><span itemprop="author">Emily G Greengard</span>, MD and <span itemprop="author">Julie R Park</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK24599_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK24599_ai__"><div class="contrib half_rhythm"><span itemprop="author">Emily G Greengard</span>, MD<div class="affiliation small">University of Minnesota Masonic Children&#x02019;s Hospital<br />Minneapolis, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nmu@gylime" class="oemail">ude.nmu@gylime</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Julie R Park</span>, MD<div class="affiliation small">Seattle Children&#x02019;s Hospital<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.snerdlihcelttaes@krap.eiluj" class="oemail">gro.snerdlihcelttaes@krap.eiluj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 5, 2010</span>; Last Update: <span itemprop="dateModified">January 17, 2019</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="alk-nbs.Summary" itemprop="description"><h2 id="_alk-nbs_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>ALK-</i>related neuroblastic tumor susceptibility is characterized by increased risk for neuroblastic tumors including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Neuroblastoma is a more malignant tumor and ganglioneuroma a more benign tumor. Depending on the histologic findings, ganglioneuroblastoma can behave in a more aggressive fashion, like neuroblastoma, or in a benign fashion, like ganglioneuroma. Preliminary data from the ten reported families with <i>ALK</i>-related neuroblastic tumor susceptibility suggest an overall <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of approximately 57% with the risk for neuroblastic tumor development highest in infancy and decreasing by late childhood.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p><i>ALK</i>-related neuroblastic tumor susceptibility is established by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that is known or suspected to cause altered kinase function.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Children who develop neuroblastic tumors should be evaluated and treated by a pediatric oncologist at a pediatric cancer center. Treatment for individuals with neuroblastoma and ganglioneuroblastoma who have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is the same standard risk-stratified therapy used to treat all neuroblastoma. Ganglioneuromas are typically removed by surgical resection and require no further therapy.</p><p><i>Surveillance:</i></p><ul><li class="half_rhythm"><div><i>Asymptomatic children</i>. Physical examination, abdominal ultrasound examination, chest x-ray, and measurement of urine catecholamine metabolite levels (homovanillic acid and vanillylmandelic acid) every three months between birth and age six years. Physical examination, abdominal ultrasound examination, chest x-ray, and measurement of urine catecholamine metabolite levels (homovanillic acid and vanillylmandelic acid) every six months between age six years and ten years. Screening beyond age ten years is not indicated.</div></li><li class="half_rhythm"><div><i>After successful treatment of a neuroblastic tumor.</i> Screening for neuroblastoma should continue since children with <i>ALK</i>-related neuroblastoma are at risk of developing multiple primary tumors. Screening should continue as described above until age ten years.</div></li></ul><p><i>Evaluation of relatives at risk:</i> It is appropriate to test relatives at risk (i.e., sibs age &#x0003c;10 years at the time of diagnosis of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, as well as sibs born subsequently) for the <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the proband to identify those for whom early detection of neuroblastoma and initiation of therapy would likely improve quality of life and possibly affect outcome (if therapy is started prior to end organ damage).</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>ALK</i>-related neuroblastic tumor susceptibility is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner, with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Some individuals diagnosed with <i>ALK</i>-related neuroblastic susceptibility have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent who may have had any one of the three neuroblastic tumor types. <i>De novo</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants have been reported; the proportion of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown. Each child of an individual with <i>ALK</i>-related neuroblastic tumor susceptibility has a 50% chance of inheriting the <i>ALK</i> pathogenic variant; however, the likelihood that a child who inherits the <i>ALK</i> pathogenic variant will develop a neuroblastic tumor is unknown. Prenatal testing is possible for pregnancies at increased risk in families in which the pathogenic variant has been identified.</p></div></div><div id="alk-nbs.GeneReview_Scope"><h2 id="_alk-nbs_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="alk-nbs.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24599/table/alk-nbs.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alk-nbs.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alk-nbs.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>ALK</i>-Related Neuroblastic Tumor Susceptibility: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_alk-nbs.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Neuroblastoma</div></li><li class="half_rhythm"><div>Ganglioneuroblastoma</div></li><li class="half_rhythm"><div>Ganglioneuroma</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alk-nbs.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#alk-nbs.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="alk-nbs.Diagnosis"><h2 id="_alk-nbs_Diagnosis_">Diagnosis</h2><div id="alk-nbs.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>ALK-</i>related neuroblastic tumor susceptibility <b>should be suspected</b> in individuals with:</p><ul><li class="half_rhythm"><div>A neuroblastic tumor including neuroblastoma, ganglioneuroblastoma, or ganglioneuroma;</div></li><li class="half_rhythm"><div>Multiple primary neuroblastic tumors that arise either synchronously or metachronously;</div></li><li class="half_rhythm"><div>A family history of one or more relatives with one of these three neuroblastic tumors. Note: Both benign and malignant tumors can occur in the same family.</div></li></ul><p>Written guidelines for selection of individuals with a neuroblastic tumor to be tested for <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants are under development, and no consensus opinion currently exists.</p><p>Considerations for testing for <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants include the following strong and moderate recommendations [<a class="bk_pop" href="#alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</a>, <a class="bk_pop" href="#alk-nbs.REF.brodeur.2017.e1">Brodeur et al 2017</a>].</p><div id="alk-nbs.Recommendations_Regarding_Testin"><h4>Recommendations Regarding Testing for Germline <i>ALK</i> Pathogenic Variants</h4><p><b>Strong recommendation</b></p><ul><li class="half_rhythm"><div class="half_rhythm">All children with documented somatic <i>ALK</i> pathogenic variants within a neuroblastic tumor</div></li><li class="half_rhythm"><div class="half_rhythm">An individual with a neuroblastic tumor* who has at least one <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> with a neuroblastic tumor</div><div class="half_rhythm">*&#x000a0;Germline <i>ALK</i> pathogenic variants are equally likely to be identified in individuals with any of the three neuroblastic tumor types and with any stage of malignant neuroblastoma [<a class="bk_pop" href="#alk-nbs.REF.liu.2012.325">Liu &#x00026; Thiele 2012</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">An individual with a neuroblastic tumor and a family history of neuroblastic tumors that are not a manifestation of a neural crest disorder such as <a href="/books/n/gene/hirschsprung-ov/">Hirschsprung disease</a> or <a href="/books/n/gene/ondine/">central hypoventilation syndrome</a>, which may suggest pathogenic variants in <i>PHOX2B</i> (See <a href="#alk-nbs.Differential_Diagnosis">Differential Diagnosis</a>.)</div></li></ul><p><b>Moderate recommendation.</b> A <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) with bilateral neuroblastoma or multifocal primary neuroblastic tumors [<a class="bk_pop" href="#alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</a>]</p><p><b>No recommendation.</b> An individual with a neuroblastic tumor and distant relatives (&#x02265;2nd degree) with a history of neuroblastic tumors, as such an individual is unlikely to have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]</p></div><div id="alk-nbs.Considerations_for_Testing_for_S"><h4>Considerations for Testing for Somatic <i>ALK</i> Pathogenic Variants</h4><p>Some institutions are currently screening tumors of all children with neuroblastoma, and others are screening tumors at the time of recurrence or progression, primarily for potential for <i>ALK</i>-directed therapy (see Molecular Genetics, <a href="#alk-nbs.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>) rather than identifying those at increased risk of having a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div></div><div id="alk-nbs.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><i>ALK</i>-related neuroblastic tumor susceptibility <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that is known or suspected to cause altered kinase function (see <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figalknbsTmoleculargenetictestingused" rid-ob="figobalknbsTmoleculargenetictestingused">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ALK</i> may detect <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> activating pathogenic variants in the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that are known or suspected to cause altered kinase function.</div><div class="half_rhythm">Note: <i>ALK</i>-related neuroblastic tumor susceptibility is postulated to occur through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism. Large intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> has not been reported; testing for intragenic deletions or duplication is not indicated.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ALK</i> and other genes of interest (see <a href="#alk-nbs.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="alk-nbs.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>ALK</i>-Related Neuroblastic Tumor Susceptibility</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24599/table/alk-nbs.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alk-nbs.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALK</i></td><td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alk-nbs.TF.1.1"><p class="no_margin">See <a href="/books/NBK24599/#alk-nbs.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="alk-nbs.TF.1.2"><p class="no_margin">See <a href="#alk-nbs.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="alk-nbs.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="alk-nbs.TF.1.4"><p class="no_margin">In families with two or more first-degree relatives with neuroblastoma, the incidence of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants is 80%. In families in which two second-degree or more distant relatives have neuroblastoma, the incidence of germline <i>ALK</i> pathogenic variants is much lower [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>].</p></div></dd><dt>5. </dt><dd><div id="alk-nbs.TF.1.5"><p class="no_margin">Somatic <i>ALK</i> activating pathogenic variants, which may be found in 7%-8% of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> neuroblastoma tumors, are rarely associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants [<a class="bk_pop" href="#alk-nbs.REF.liu.2012.325">Liu &#x00026; Thiele 2012</a>]. In 167 tumors tested from <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases with high-risk neuroblastomas, <a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al [2008]</a> found that 14 had somatic <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that were predicted to be activating. Of these 14 individuals with somatic <i>ALK</i> missense variants, germline DNA was available on nine. In one of those nine individuals the <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Ile1250Thr</a>, was identified in both germline and tumor DNA.</p></div></dd><dt>6. </dt><dd><div id="alk-nbs.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div><div id="alk-nbs.Clinical_Characteristics"><h2 id="_alk-nbs_Clinical_Characteristics_">Clinical Characteristics</h2><div id="alk-nbs.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with <i>ALK</i>-related neuroblastic tumor susceptibility are at risk of developing a spectrum of neuroblastic tumors that include neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Within this spectrum, neuroblastoma represents a more malignant tumor and ganglioneuroma a more benign tumor. The three neuroblastic tumor types are defined histologically. Depending on the histologic findings, ganglioneuroblastoma can behave in a benign fashion, like ganglioneuroma, or in a more aggressive fashion, like neuroblastoma.</p><p>Data from the ten reported families with <i>ALK</i>-related neuroblastic tumor susceptibility suggest that the overall <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of this cancer predisposition syndrome is around 57% [<a class="bk_pop" href="#alk-nbs.REF.eng.2008.883">Eng 2008</a>]. A recent study showed that 45%-50% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will develop a neuroblastic tumor in their lifetime [<a class="bk_pop" href="#alk-nbs.REF.brodeur.2017.e1">Brodeur et al 2017</a>].</p><p>Risk for neuroblastic tumor development is highest in infancy and decreases by late childhood, with 98% of neuroblastic tumors occurring by age ten years [<a class="bk_pop" href="#alk-nbs.REF.brodeur.2017.e1">Brodeur et al 2017</a>]. Individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> neuroblastoma tend to develop tumors at a younger age (average 9 months) than those without familial predisposition (age 2-3 years) [<a class="bk_pop" href="#alk-nbs.REF.park.2008.97">Park et al 2008</a>].</p><p><b>Multiple primary tumors.</b> Individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> neuroblastoma also have a higher-than-average incidence of multiple primary tumors [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.park.2008.97">Park et al 2008</a>]. The multiple primary tumors may be bilateral adrenal tumors or multiple primary extra-adrenal tumors arising at sites of sympathetic ganglions. The tumors can occur either synchronously or metachronously [<a class="bk_pop" href="#alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</a>].</p><p><b>Outcome.</b> Given the rarity of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> neuroblastic tumors, statistically significant long-term outcome data are not yet available for individuals with <i>ALK</i>-related neuroblastic tumor susceptibility. Although long-term survivors of neuroblastoma who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an inherited <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported [<a class="bk_pop" href="#alk-nbs.REF.car_n.2008.153">Car&#x000e9;n et al 2008</a>], no prospective studies have evaluated the survival of persons with a germline <i>ALK</i> pathogenic variant compared to those with neuroblastoma not associated with a germline <i>ALK</i> pathogenic variant.</p><p>Since neuroblastomic tumor outcome is heavily dependent on biologic characteristics and stage of the tumor, it is likely that survival from a neuroblastic tumor depends more on tumor type (neuroblastoma having the poorest outcome), tumor stage, and appropriate medical intervention than on the presence or absence of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#alk-nbs.REF.park.2008.97">Park et al 2008</a>].</p></div><div id="alk-nbs.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Aside from the following pathogenic variants, no associations between specific <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants and risk of developing neuroblastoma or outcome of neuroblastoma have been established [<a class="bk_pop" href="#alk-nbs.REF.azarova.2011.267">Azarova et al 2011</a>].</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Arg1275Gln</a>, found in approximately 45% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#alk-nbs.REF.wood.2009">Wood et al 2009</a>], may be associated with somewhat decreased <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (40%).</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Gly1128Ala</a>, reported as a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one large family, appeared to have lower <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>: 40% of heterozygotes developed a neuroblastoma during childhood [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]. Adult heterozygotes were healthy; no tumor types other than neuroblastoma were reported.</div></li></ul></div><div id="alk-nbs.Penetrance"><h3>Penetrance</h3><p>The overall <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is approximately 50% [<a class="bk_pop" href="#alk-nbs.REF.brodeur.2017.e1">Brodeur et al 2017</a>]. Several obligate <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> asymptomatic adults have been identified [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</a>]. In at least one family, a child with neuroblastoma inherited the <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Arg1275Gln</a> pathogenic variant from an unaffected father [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>].</p><p>See also <a href="#alk-nbs.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a> for information on <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div><div id="alk-nbs.Prevalence"><h3>Prevalence</h3><p>Familial neuroblastoma occurs in approximately 1%-2% of all individuals with neuroblastoma [<a class="bk_pop" href="#alk-nbs.REF.weiss.2016.2133">Weiss et al 2016</a>]. Of those <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases, <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> pathogenic variants in <i>ALK</i> account for 75% [<a class="bk_pop" href="#alk-nbs.REF.ritenour.2018.287">Ritenour et al 2018</a>].</p></div></div><div id="alk-nbs.Genetically_Related_Allelic_Diso"><h2 id="_alk-nbs_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p><b>Germline <i>ALK</i> pathogenic variants.</b> The majority of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have no obvious <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> other than predisposition to neuroblastoma. The exceptions are the pathogenic variants (<a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Phe1174Val</a> and <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Phe1245Val</a>) identified in the germline in two unrelated children with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> neuroblastoma, severe developmental delay, and structural brain stem abnormalities. Although these pathogenic variants have been reported as somatic variants in neuroblastoma tumors, they have not been reported in the germline of phenotypically normal individuals with neuroblastoma [<a class="bk_pop" href="#alk-nbs.REF.de_pontual.2011.272">de Pontual et al 2011</a>].</p><p><b>Sporadic tumors</b> (including neuroblastomas) occurring as single tumors in the absence of any other findings of this syndrome frequently harbor somatic variants in <i>ALK</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>; thus, predisposition to these tumors is not heritable. For more details see Molecular Genetics, <a href="#alk-nbs.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div><div id="alk-nbs.Differential_Diagnosis"><h2 id="_alk-nbs_Differential_Diagnosis_">Differential Diagnosis</h2><p>Germline pathogenic variants in <i>ALK</i> and <i>PHOX2B</i> are the etiologic agents for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> neuroblastoma susceptibility.</p><ul><li class="half_rhythm"><div>Heterozygous <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants are the main cause of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> susceptibility to neuroblastoma in otherwise healthy individuals.</div></li><li class="half_rhythm"><div>Heterozygous <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>PHOX2B</i> pathogenic variants account for the remainder of families, most of whom also have disorders of neural crest development [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.azarova.2011.267">Azarova et al 2011</a>].</div></li></ul><p><i>PHOX2B</i>-related neuroblastoma susceptibility and other disorders to consider in the differential diagnosis of <i>ALK</i>-related neuroblastic tumor susceptibility are summarized in <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.disorders_to_consider_in_the_d/?report=objectonly" target="object" rid-figpopup="figalknbsTdisorderstoconsiderinthed" rid-ob="figobalknbsTdisorderstoconsiderinthed">Table 2</a>.</p><div id="alk-nbs.T.disorders_to_consider_in_the_d" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of <i>ALK</i>-Related Neuroblastic Tumor Susceptibility (<i>ALK</i>-NTS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24599/table/alk-nbs.T.disorders_to_consider_in_the_d/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alk-nbs.T.disorders_to_consider_in_the_d_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4" id="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/<i>ALK</i>-NTS</th><th headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4" id="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from <i>ALK</i>-NTS</th></tr></thead><tbody><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PHOX2B</i>-related <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> neuroblastoma susceptibility (OMIM <a href="https://omim.org/entry/613013" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613013</a>)</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PHOX2B</i></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial neuroblastoma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div><a href="/books/n/gene/hirschsprung-ov/">Hirschsprung disease</a></div></li><li class="half_rhythm"><div>Decreased esophageal motility</div></li><li class="half_rhythm"><div><a href="/books/n/gene/ondine/">Congenital central hypoventilation syndrome</a></div></li><li class="half_rhythm"><div>Dysmorphic facial features (downslanting palpebral fissures, small nose, triangular mouth, low-set, posteriorly rotated ears)</div></li></ul>
</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ROHHAD syndrome&#x000a0;<sup>1</sup></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ganglioneuroblastoma, ganglioneuroma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Rapid-onset obesity</div></li><li class="half_rhythm"><div>Hypothalamic dysfunction</div></li><li class="half_rhythm"><div>Hypoventilation</div></li><li class="half_rhythm"><div>Autonomic dysregulation</div></li></ul>
</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KIF1B</i>-neuroblastoma susceptibility (OMIM <a href="https://omim.org/entry/256700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">256700</a>)</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KIF1B</i></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuroblastoma, ganglioneuroma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pheochromocytomas, leiomyosarcoma</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/nf1/">Neurofibromatosis 1</a></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NF1</i></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuroblastoma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Caf&#x000e9; au lait macules, intertriginous freckling, cutaneous neurofibromas</div></li><li class="half_rhythm"><div>Peripheral nerve sheath tumors</div></li><li class="half_rhythm"><div>Iris Lisch nodules</div></li><li class="half_rhythm"><div>Learning disabilities</div></li></ul>
</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/costello/">Costello syndrome</a></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HRAS</i></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuroblastoma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Characteristic facies</div></li><li class="half_rhythm"><div>Growth deficiency</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Characteristic hair &#x00026; skin findings</div></li><li class="half_rhythm"><div>Cardiac disease</div></li></ul>
</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/noonan/">Noonan syndrome</a></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;8 genes</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuroblastoma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Characteristic facies</div></li><li class="half_rhythm"><div>Short stature</div></li><li class="half_rhythm"><div>Congenital heart disease</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Leukemias, rhabdomyosarcoma</div></li></ul>
</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/li-fraumeni/">Li-Fraumeni syndrome</a></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TP53</i></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuroblastoma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Soft-tissue sarcomas, osteosarcoma, breast cancer, brain tumors, adrenocortical carcinoma, leukemias</td></tr><tr><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bws/">Beckwith-Weidemann syndrome</a></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:justify;vertical-align:middle;"><i>CDKN1C</i>&#x000a0;<sup>2</sup></td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Simplex or AD</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuroblastoma</td><td headers="hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_1_4 hd_h_alk-nbs.T.disorders_to_consider_in_the_d_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Macrosomia, macroglossia, visceromegaly, omphalocele, neonatal hypoglycemia, ear creases/pits, adrenocortical cytomegaly, renal abnormalities, hemihyperplasia</div></li><li class="half_rhythm"><div>Wilms tumor, hepatoblastoma, rhabdomyosarcoma</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="alk-nbs.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#alk-nbs.REF.izeludlow.2007.e179">Ize-Ludlow et al [2007]</a></p></div></dd><dt>2. </dt><dd><div id="alk-nbs.TF.2.2"><p class="no_margin">Beckwith-Wiedemann syndrome is associated with abnormal regulation of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> transcription in the <a class="def" href="/books/n/gene/glossary/def-item/imprinted/">imprinted</a> <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 11p15.5, which can be caused by different genetic mechanisms: abnormal <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> of one of two differently methylated regions (DMRs), paternal <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a>, or pathogenic variants in <i>CDKN1C</i>.</p></div></dd></dl></div></div></div></div><div id="alk-nbs.Management"><h2 id="_alk-nbs_Management_">Management</h2><div id="alk-nbs.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>ALK</i>-related neuroblastic tumor susceptibility, the evaluations summarized in this section are recommended:</p><ul><li class="half_rhythm"><div>Physical examination to assess for clinical manifestations of neuroblastic tumors such as an abdominal mass, Horner syndrome, and/or cutaneous lesions</div></li><li class="half_rhythm"><div>Radiograph of the chest and ultrasound examination of the abdomen, the most common sites for neuroblastic tumor development</div></li><li class="half_rhythm"><div>Measurement of urine catecholamines, as homovanillic acid and vanillylmandelic acid may be elevated in the presence of a neuroblastic tumor</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="alk-nbs.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Children who develop neuroblastic tumors (neuroblastomas, ganglioneuroblastoma, or ganglioneuroma) should be evaluated and treated by a pediatric oncologist at a pediatric cancer center.</p><p><b>Neuroblastoma and ganglioneuroblastoma.</b> The treatment for individuals with a neuroblastic tumor who have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is the same standard risk-stratified therapy used to treat all neuroblastic tumors. Clinical trials are ongoing to study the efficacy of <i>ALK</i>-targeted therapy in the setting of relapsed and refractory neuroblastoma and ganglioneuroblastoma (see <a href="#alk-nbs.Therapies_Under_Investigation">Therapies Under Investigation</a>).</p><p>The management guidelines for neuroblastoma or ganglioneuroblastoma are complex [<a class="bk_pop" href="#alk-nbs.REF.irwin.2015.225">Irwin &#x00026; Park 2015</a>]:</p><ul><li class="half_rhythm"><div>Depending on the age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, stage of the tumor, and biologic characteristics of the tumor, treatment may involve observation or surgical resection.</div></li><li class="half_rhythm"><div>Tumors with risk for metastatic spread or those that have already metastasized require chemotherapy and sometimes radiation therapy, stem cell transplantation, and immunotherapy.</div></li></ul><p><b>Ganglioneuromas</b> are typically removed by surgical resection and require no further therapy.</p></div><div id="alk-nbs.Surveillance"><h3>Surveillance</h3><p><b>Asymptomatic children at risk.</b> Guidelines for the screening of individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> neuroblastoma &#x02013; including those with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating pathogenic variants &#x02013; were published in 2017 [<a class="bk_pop" href="#alk-nbs.REF.brodeur.2017.e1">Brodeur et al 2017</a>]. These surveillance recommendations include physical examination, abdominal ultrasound examination, chest x-ray, and measurement of urine catecholamine metabolite levels (homovanillic acid and vanillylmandelic acid) at the following frequency:</p><ul><li class="half_rhythm"><div><b>Birth to age 6 years.</b> Every three months</div></li><li class="half_rhythm"><div><b>Age 6-10 years.</b> Every six months</div></li></ul><p>Screening beyond age ten years is not indicated.</p><p><b>After successful treatment of a neuroblastic tumor,</b> screening for neuroblastic tumors should continue since children with <i>ALK</i>-related neuroblastic tumor susceptibility are at risk of developing multiple primary tumors. Screening should continue as described above until ten years of age.</p></div><div id="alk-nbs.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>There is currently no evidence that individuals with <i>ALK</i>-related neuroblastoma tumor susceptibility have increased sensitivity to chemotherapeutic agents or radiation therapy; thus, medical and surgical management of tumors should be the same as for the general population.</p></div><div id="alk-nbs.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to test sibs younger than age ten years at the time of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s diagnosis as well as sibs born subsequently for the <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the proband. Genetic testing identifies sibs at high risk for neuroblastoma, for whom early detection of neuroblastoma and initiation of therapy would likely improve quality of life and may affect outcome (if therapy is started prior to end organ damage).</p><p>Note: Sibs of all probands with neuroblastoma have an increased chance of developing neuroblastoma themselves, with a standardized incidence ratio of 9.7 compared to the general population [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]. This increased risk is likely due in part to the possibility of inherited <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> pathogenic variants in some children with neuroblastoma.</p><p>See <a href="#alk-nbs.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="alk-nbs.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several early-phase clinical trials of small-molecule inhibitors targeting the ALK tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> have been completed in individuals with <i>ALK-</i>aberrant neuroblastoma. In addition, several trials are ongoing. The role of these agents for the treatment of <i>ALK-</i>aberrant neuroblastoma is yet to be elucidated. Currently, the Children's Oncology Group Phase III trial for children with high-risk neuroblastoma is incorporating the ALK inhibitor crizotinib into the frontline treatment for individuals whose tumors harbor an <i>ALK</i> aberration.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="alk-nbs.Genetic_Counseling"><h2 id="_alk-nbs_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="alk-nbs.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>ALK</i>-related neuroblastic tumor susceptibility is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="alk-nbs.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Some individuals diagnosed with <i>ALK</i>-related neuroblastic susceptibility inherited an <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent.</div><ul><li class="half_rhythm"><div>Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, a parent may have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> without having developed a neuroblastic tumor (neuroblastoma, ganglioneuroma, or ganglioneuroblastoma) [<a class="bk_pop" href="#alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>].</div></li><li class="half_rhythm"><div>As yet, no tumor types other than neuroblastoma, ganglioneuroma, or ganglioneuroblastoma have been reported to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating pathogenic variants and no data regarding the cancer risk for <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> adult parents of a child with <i>ALK</i>-related neuroblastic susceptibility have been published.</div></li></ul></li><li class="half_rhythm"><div>Some individuals diagnosed with <i>ALK</i>-related neuroblastic tumor susceptibility may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. <i>De novo</i> germline pathogenic variants have been reported; their proportion is unknown.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of a proband inheriting a pathogenic variant from a parent with germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with <i>ALK</i>-related neuroblastic tumor susceptibility may appear to be negative because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> or failure to recognize the disorder in family members. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has confirmed that neither of the parents has the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the pathogenic variant is 50%. The likelihood that a sib who inherits the <i>ALK</i> pathogenic variant will develop a neuroblastic tumor is not yet definitively known, but likely a 45%-50% chance.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#alk-nbs.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents whose <i>ALK</i> variant status is unknown are still at increased risk (for the disorder) because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with <i>ALK</i>-related neuroblastic tumor susceptibility has a 50% chance of inheriting the <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The likelihood that a child who inherits the <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will develop a neuroblastic tumor is unknown, though the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is high (57%) [<a class="bk_pop" href="#alk-nbs.REF.eng.2008.883">Eng 2008</a>] and the relative risk (compared to a child in the general population) of developing a neuroblastic tumor is substantial.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk for neuroblastoma or related tumors.</p></div><div id="alk-nbs.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#alk-nbs.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Testing of at-risk asymptomatic relatives</b> of individuals with <i>ALK</i>-related neuroblastic tumor susceptibility is possible after <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified the specific <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family. Although molecular genetic testing can identify the presence of an <i>ALK</i> pathogenic variant, it cannot predict whether neuroblastoma, ganglioneuroma, or ganglioneuroblastoma will develop.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, or are at risk of having a germline <i>ALK</i> activating pathogenic variant.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="alk-nbs.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Note: Although <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can identify the presence of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, it cannot predict whether neuroblastoma will develop.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="alk-nbs.Resources"><h2 id="_alk-nbs_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Children's Neuroblastoma Cancer Foundation</b></div><div>PO Box 6635</div><div>Bloomingdale IL 60108</div><div><b>Phone:</b> 866-671-2623 (toll-free)</div><div><b>Fax:</b> 630-351-2462</div><div><b>Email:</b> info@nbhope.org</div><div><a href="http://www.cncfhope.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cncfhope.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=ALK-Related%20Neuroblastoma%20Susceptibility&#x00026;parent=Disease%20Risk&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALK-Related Neuroblastoma Susceptibility</a></div></li><li class="half_rhythm"><div><b>American Cancer Society (ACS)</b></div><div>250 Williams Street Northwest</div><div>Atlanta GA 30303</div><div><b>Phone:</b> 800-227-2345 (toll-free 24/7); 866-228-4327 (toll-free 24/7 TTY)</div><div><a href="http://www.cancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.org</a></div></li><li class="half_rhythm"><div><b>American Childhood Cancer Organization (ACCO)</b></div><div>6868 Distribution Drive</div><div>Beltsville MD 20705</div><div><b>Phone:</b> 855-858-2226 (toll-free); 301-962-3520</div><div><b>Fax:</b> 301-962-3521</div><div><b>Email:</b> staff@acco.org</div><div><a href="http://www.acco.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.acco.org</a></div></li><li class="half_rhythm"><div><b>CancerCare</b></div><div>275 Seventh Avenue</div><div>22nd Floor</div><div>New York NY 10001</div><div><b>Phone:</b> 800-813-4673 (toll-free); 212-712-8400 (administrative)</div><div><b>Fax:</b> 212-712-8495</div><div><b>Email:</b> info@cancercare.org</div><div><a href="http://www.cancercare.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancercare.org</a></div></li></ul></div><div id="alk-nbs.Molecular_Genetics"><h2 id="_alk-nbs_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="alk-nbs.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>ALK-Related Neuroblastic Tumor Susceptibility: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24599/table/alk-nbs.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alk-nbs.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_alk-nbs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_alk-nbs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_alk-nbs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_alk-nbs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_alk-nbs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_alk-nbs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_alk-nbs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/238" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ALK</i></a></td><td headers="hd_b_alk-nbs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=238" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p23<wbr style="display:inline-block"></wbr>​.2-p23.1</a></td><td headers="hd_b_alk-nbs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UM73" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALK tyrosine kinase receptor</a></td><td headers="hd_b_alk-nbs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ALK" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALK database</a></td><td headers="hd_b_alk-nbs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ALK" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALK</a></td><td headers="hd_b_alk-nbs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ALK[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALK</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="alk-nbs.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="alk-nbs.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for ALK-Related Neuroblastic Tumor Susceptibility (<a href="/omim/105590,613014" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24599/table/alk-nbs.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alk-nbs.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/105590" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">105590</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ANAPLASTIC LYMPHOMA KINASE; ALK</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613014" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613014</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEUROBLASTOMA, SUSCEPTIBILITY TO, 3; NBLST3</td></tr></tbody></table></div></div><div id="alk-nbs.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p><i>ALK</i> is predicted to function as an oncogene in the pathogenesis of neuroblastoma [<a class="bk_pop" href="#alk-nbs.REF.chen.2008.971">Chen et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.george.2008.975">George et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]. Somatic chromosomal translocations causing constitutive activation of <i>ALK</i> are known to mediate malignant transformation in other types of tumors such as non-small-cell lung cancer (<i>ALK/EML4</i> fusion protein) and anaplastic large-cell lymphoma (<i>ALK/NPM1</i>) [<a class="bk_pop" href="#alk-nbs.REF.palmer.2009.345">Palmer et al 2009</a>].</p><p>In <i>ALK</i>-related neuroblastoma, both <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> and somatic pathogenic variants are found exclusively within the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>ALK</i>. These pathogenic variants lead to constitutive phosphorylation and activation of the ALK protein. Somatic amplification of <i>ALK</i> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2p23 has also been identified in a subset of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> neuroblastomas with unfavorable biologic characteristics and aggressive clinical course.</p><p><b>Gene structure.</b>
<i>ALK</i> comprises 29 coding exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK24599/#alk-nbs.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The vast majority (91%) of <i>ALK</i> pathogenic variants fall within the kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> [<a class="bk_pop" href="#alk-nbs.REF.chen.2008.971">Chen et al 2008</a>]. Missense variants in the tyrosine kinase domain of <i>ALK</i> are associated with <i>ALK</i>-related neuroblastic tumor susceptibility [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>].</p><p>The variant <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Arg1275Gln</a>, the most commonly reported <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, is found in approximately 45% of individuals with a germline pathogenic variant [<a class="bk_pop" href="#alk-nbs.REF.wood.2009">Wood et al 2009</a>]; it is also the most common <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a>.</p><div id="alk-nbs.T.alk_germline_pathogenic_varian" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>ALK</i> Germline Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alk-nbs.T.alk_germline_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3383G&#x0003e;C</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly1128Ala</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nucleotide/29029631" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004304<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/29029632" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004295<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3452C&#x0003e;T</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr1151Met&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3749T&#x0003e;C</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile1250Thr&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3520T&#x0003e;G</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe1174Val&#x000a0;<sup>3,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3733T&#x0003e;G</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe1245Val&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3824G&#x0003e;A</td><td headers="hd_h_alk-nbs.T.alk_germline_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1275Gln&#x000a0;<sup>4,&#x000a0;5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="alk-nbs.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#alk-nbs.REF.george.2008.975">George et al [2008]</a></p></div></dd><dt>2. </dt><dd><div id="alk-nbs.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al [2008]</a></p></div></dd><dt>3. </dt><dd><div id="alk-nbs.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#alk-nbs.REF.de_pontual.2011.272">de Pontual et al [2011]</a></p></div></dd><dt>4. </dt><dd><div id="alk-nbs.TF.3.4"><p class="no_margin">Most common <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></p></div></dd><dt>5. </dt><dd><div id="alk-nbs.TF.3.5"><p class="no_margin">See <a href="#alk-nbs.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ALK</i> encodes a 1,620-amino acid protein that is a single chain receptor tyrosine kinase; its normal function is not known [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]. Expression is restricted to the developing central and peripheral nervous system with a postulated role in regulation of neuronal differentiation.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>ALK</i> result in constitutive phosphorylation [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>] and are predicted with high probability to drive oncogenesis [<a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]. Both <i>ALK</i> pathogenic variants and amplifications have been shown to have direct oncogenic effect, as evidenced by autophosphorylation of mutated strains and activation of downstream targets in neuroblastoma cell lines harboring <i>ALK</i> pathogenic variants and amplification [<a class="bk_pop" href="#alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>]. Tumors with aberrant <i>ALK</i> signaling display transforming potential in vivo, inducing soft agar colony formation in mutated cell lines, rapid tumor growth in nude mice, and increased apoptosis in response to small interfering or small-hairpin RNA targeted against <i>ALK</i> [<a class="bk_pop" href="#alk-nbs.REF.chen.2008.971">Chen et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.george.2008.975">George et al 2008</a>, <a class="bk_pop" href="#alk-nbs.REF.park.2008.97">Park et al 2008</a>].</p></div><div id="alk-nbs.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p>Fusion proteins resulting from somatic translocations involving <i>ALK</i> have been implicated in several types of cancer. In all these tumors, aberrant ALK signaling occurs as a result of a <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> involving the <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> at 2p23. In contrast, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> and somatic <i>ALK</i> pathogenic variants have only been discovered in neuroblastoma.</p><p><b>Fusion proteins</b></p><ul><li class="half_rhythm"><div>Anaplastic large-cell lymphomas harbor a characteristic <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2;5 <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> involving <i>ALK</i> and <i>NPM1</i> (encoding nucleophosmin), which may be referred to as <i>ALK/NPM1</i> [<a class="bk_pop" href="#alk-nbs.REF.morris.1994.1281">Morris et al 1994</a>].</div></li><li class="half_rhythm"><div><i>ALK/EML4</i> fusion transcripts are found in a subset of individuals with non-small-cell lung cancer, all of whom lack <i>EGFR</i> pathogenic variants [<a class="bk_pop" href="#alk-nbs.REF.soda.2007.561">Soda et al 2007</a>].</div></li><li class="half_rhythm"><div><i>ALK</i> fusion proteins have also been described in inflammatory myofibroblastic tumors, diffuse large B-cell lymphomas, and squamous cell carcinomas of the esophagus [<a class="bk_pop" href="#alk-nbs.REF.palmer.2009.345">Palmer et al 2009</a>].</div></li></ul><p><b>Somatic <i>ALK</i> pathogenic variants.</b> The frequency of somatic <i>ALK</i> pathogenic variants involving neuroblastoma tumor tissue is 6%-12% [Santani A &#x00026; Maris J, personal communication]. Disruption of normal <i>ALK</i> signaling is likely to play a critical role in neuroblastic tumor pathogenesis. Furthermore, it appears that individuals whose tumor harbors a somatic <i>ALK</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or <i>ALK</i> amplification (i.e., &#x0003e;10 copies of <i>ALK</i>) have a poorer prognosis than individuals with otherwise similar tumor stage and biology [<a class="bk_pop" href="#alk-nbs.REF.chen.2008.971">Chen et al 2008</a>; <a class="bk_pop" href="#alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</a>; <a class="bk_pop" href="#alk-nbs.REF.moss_.2013.472">Moss&#x000e9; et al 2013</a>; Santani A &#x00026; Maris J, personal communication].</p><p>Preclinical data suggest that responsiveness to crizotinib may depend on the presence or absence and specific type of somatic <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., in the tumor). Specifically, tumors with the somatic <i>ALK</i> pathogenic variants p.Phe1174Leu, p.Gly1128Ala, p.Met1166Arg, p.Phe1245Cys, p.Phe1245Val, and p.Tyr1278Ser are relatively crizotinib resistant, whereas the p.Ile1170Asn, p.Ile1170Ser, p.Ile1171Asn, p.Leu1196Met, and p.Arg1275Gln variants are sensitive to crizotinib. The p.Arg1192Pro variant is intermediate in sensitivity [<a class="bk_pop" href="#alk-nbs.REF.moss_.2013.472">Moss&#x000e9; et al 2013</a>]. Subsequent Phase II and III clinical trials for neuroblastoma will incorporate <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the tumors of all individuals enrolled in the trial.</p><p>These data have been confirmed in other studies as well. For example, human neuroblastoma-derived cell lines harboring mutated proteins with the <a class="figpopup" href="/books/NBK24599/table/alk-nbs.T.alk_germline_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalknbsTalkgermlinepathogenicvarian" rid-ob="figobalknbsTalkgermlinepathogenicvarian">p.Arg1275Gln</a> substitution, the most common abnormal protein described in <i>ALK</i>-related neuroblastoma [<a class="bk_pop" href="#alk-nbs.REF.azarova.2011.267">Azarova et al 2011</a>], were more sensitive to the small-molecule <i>ALK</i> inhibitor PF-02341066 than cell lines harboring proteins with the p.Phe1174Leu substitution or those without <i>ALK</i> aberrations [<a class="bk_pop" href="#alk-nbs.REF.wood.2009">Wood et al 2009</a>]. The cell line most sensitive to pharmacologic inhibition harbors high-level amplification of <i>ALK</i> (wild type sequence). Clinical correlation in individuals with neuroblastoma has yet to be determined [<a class="bk_pop" href="#alk-nbs.REF.wood.2009">Wood et al 2009</a>].</p><p>The variant p.Phe1174Leu, associated with amplification of the oncogene <i>MYCN</i>, is found as a <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> in 30% of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> neuroblastoma tumors that harbor an <i>ALK</i> pathogenic variant [<a class="bk_pop" href="#alk-nbs.REF.carpenter.2012.391">Carpenter &#x00026; Moss&#x000e9; 2012</a>]. Individuals with this pathogenic variant have a worse prognosis than individuals with <i>MYCN</i> amplification alone [<a class="bk_pop" href="#alk-nbs.REF.azarova.2011.267">Azarova et al 2011</a>].</p></div></div><div id="alk-nbs.References"><h2 id="_alk-nbs_References_">References</h2><div id="alk-nbs.Published_Guidelines__Consensus"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF1">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <a href="http://jco.ascopubs.org/content/28/5/893.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 1-07-19.</div></li></ul></div><div id="alk-nbs.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.azarova.2011.267">Azarova AM, Gautam G, George RE. Emerging importance of ALK in neuroblastoma. <span><span class="ref-journal">Semin Cancer Biol. </span>2011;<span class="ref-vol">21</span>:267–75.</span> [<a href="/pmc/articles/PMC3242371/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3242371</span></a>] [<a href="/pubmed/21945349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21945349</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.bourdeaut.2012.291">Bourdeaut F, Ferrand S, Brugi&#x000e8;res L, Hilbert M, Ribeiro A, Lacroix L, B&#x000e9;nard J, Combaret V, Michon J, Valteau-Couanet D, Isidor B, Rialland X, Poir&#x000e9;e M, Defachelles AS, Peuchmaur M, Schleiermacher G, Pierron G, Gauthier-Villars M, Janoueix-Lerosey I, Delattre O, et al.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:291–7.</span> [<a href="/pmc/articles/PMC3283184/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3283184</span></a>] [<a href="/pubmed/22071890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22071890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.brodeur.2017.e1">Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D. Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. <span><span class="ref-journal">Knudson Jr. Clin Cancer Res. </span>2017;<span class="ref-vol">23</span>:e1–e5.</span> [<a href="/pmc/articles/PMC5553563/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5553563</span></a>] [<a href="/pubmed/28572261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28572261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.car_n.2008.153">Car&#x000e9;n H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. <span><span class="ref-journal">Biochem J. </span>2008;<span class="ref-vol">416</span>:153–9.</span> [<a href="/pubmed/18990089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18990089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.carpenter.2012.391">Carpenter EL, Moss&#x000e9; YP. Targeting ALK in neuroblastoma--preclinical and clinical advancements. <span><span class="ref-journal">Nat Rev Clin Oncol. </span>2012;<span class="ref-vol">9</span>:391–9.</span> [<a href="/pmc/articles/PMC3683972/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3683972</span></a>] [<a href="/pubmed/22585002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22585002</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.chen.2008.971">Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">455</span>:971–4.</span> [<a href="/pubmed/18923524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18923524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.de_pontual.2011.272">de Pontual L, Kettaneh D, Gordon CT, Oufadem M, Boddaert N, Lees M, Balu L, Lachassinne E, Petros A, Mollet J, Wilson LC, Munnich A, Brugi&#x000e8;re L, Delattre O, Vekemans M, Etchevers H, Lyonnet S, Janoueix-Lerosey I, Amiel J. Germline gain-of-function mutations of ALK disrupt central nervous system development. <span><span class="ref-journal">Hum Mutat. </span>2011;<span class="ref-vol">32</span>:272–6.</span> [<a href="/pubmed/21972109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21972109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.eng.2008.883">Eng C. Cancer: a ringleader identified. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">455</span>:883–4.</span> [<a href="/pubmed/18923503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18923503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.george.2008.975">George RE, Sanda T, Hanna M, Fr&#x000f6;hling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">455</span>:975–8.</span> [<a href="/pmc/articles/PMC2587486/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2587486</span></a>] [<a href="/pubmed/18923525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18923525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.irwin.2015.225">Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. <span><span class="ref-journal">Pediatr Clin North Am. </span>2015;<span class="ref-vol">62</span>:225–56.</span> [<a href="/pubmed/25435121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25435121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.izeludlow.2007.e179">Ize-Ludlow D, Gray J, Sperling MA, Berry-Kravis EM, Milunsky JM, Farooqi IS, Rand CM, Weese-Mayer DE. Rapid onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. <span><span class="ref-journal">Pediatrics. </span>2007;<span class="ref-vol">120</span>:e179–88.</span> [<a href="/pubmed/17606542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17606542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey I, Lequin D, Brugi&#x000e8;res L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">455</span>:967–70.</span> [<a href="/pubmed/18923523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18923523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.liu.2012.325">Liu Z, Thiele CJ. ALK and MYCN: when two oncogenes are better than one. <span><span class="ref-journal">Cancer Cell. </span>2012;<span class="ref-vol">21</span>:325–6.</span> [<a href="/pmc/articles/PMC3322412/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3322412</span></a>] [<a href="/pubmed/22439928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22439928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.morris.1994.1281">Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. <span><span class="ref-journal">Science. </span>1994;<span class="ref-vol">263</span>:1281–4.</span> [<a href="/pubmed/8122112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8122112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">455</span>:930–5.</span> [<a href="/pmc/articles/PMC2672043/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2672043</span></a>] [<a href="/pubmed/18724359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18724359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.moss_.2013.472">Moss&#x000e9; YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. <span><span class="ref-journal">Lancet Oncol. </span>2013;<span class="ref-vol">14</span>:472–80.</span> [<a href="/pmc/articles/PMC3730818/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3730818</span></a>] [<a href="/pubmed/23598171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23598171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.palmer.2009.345">Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. <span><span class="ref-journal">Biochem J. </span>2009;<span class="ref-vol">420</span>:345–61.</span> [<a href="/pmc/articles/PMC2708929/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2708929</span></a>] [<a href="/pubmed/19459784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19459784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.park.2008.97">Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. <span><span class="ref-journal">Pediatr Clin North Am. </span>2008;<span class="ref-vol">55</span>:97–120.</span> [<a href="/pubmed/18242317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18242317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.ritenour.2018.287">Ritenour LE, Randall M, Bosse K, Diskin S. Genetic susceptibility to neuroblastoma: current knowledge and future directions. <span><span class="ref-journal">Cell Tissue Res. </span>2018;<span class="ref-vol">372</span>:287–307.</span> [<a href="/pmc/articles/PMC6893873/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6893873</span></a>] [<a href="/pubmed/29589100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29589100</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.soda.2007.561">Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">448</span>:561–6.</span> [<a href="/pubmed/17625570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17625570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.weiss.2016.2133">Weiss T, Taschner-Mandl S, Bileck A, Slany A, Kromp F, Rifatbegovic F, Frech C, Windhager R, Kitzinger H, Tzou CH, Ambros PF, Gerner C, Ambros IM. Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype. <span><span class="ref-journal">Glia. </span>2016;<span class="ref-vol">64</span>:2133–53.</span> [<a href="/pubmed/27545331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27545331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alk-nbs.REF.wood.2009">Wood AC, Laudenslager EA, Haglund EA, Attiyeh EF, Pawel B, Courtright J, Plegaria J, Christensen JG, Maris JM, Mosse YP. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. Abstract 10008b. Orlando, FL: American Society of Clinical Oncology Annual Meeting; 2009.</div></li></ul></div></div><div id="alk-nbs.Chapter_Notes"><h2 id="_alk-nbs_Chapter_Notes_">Chapter Notes</h2><div id="alk-nbs.Author_History"><h3>Author History</h3><p>Emily G Greengard, MD (2015-present)<br />Rebecca H Johnson, MD; Seattle Children's Hospital (2009-2015)<br />Julie R Park, MD (2009-present)</p></div><div id="alk-nbs.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 January 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 April 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 May 2013 (cd) Revision: <i>ALK</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available clinically</div></li><li class="half_rhythm"><div>27 September 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 January 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>14 August 2009 (rhj) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK24599</span><span class="label">PMID: <a href="/pubmed/20301782" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301782</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ipa/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/iahsp/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK24599&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK24599/?report=reader">PubReader</a></li><li><a href="/books/NBK24599/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK24599" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK24599" style="display:none" title="Cite this Page"><div class="bk_tt">Greengard EG, Park JR. ALK-Related Neuroblastic Tumor Susceptibility. 2010 Jan 5 [Updated 2019 Jan 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK24599/pdf/Bookshelf_NBK24599.pdf">PDF version of this page</a> (460K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#alk-nbs.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#alk-nbs.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#alk-nbs.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#alk-nbs.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#alk-nbs.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#alk-nbs.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#alk-nbs.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#alk-nbs.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#alk-nbs.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#alk-nbs.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#alk-nbs.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#alk-nbs.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=238[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ALK</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=23095[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KIF1B</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK24599+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1947908" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1947908" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1947908" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1947908" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29215836" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rhabdoid Tumor Predisposition Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rhabdoid Tumor Predisposition Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nemes K, Bens S, Bourdeaut F, Hasselblatt M, Kool M, Johann P, Kordes U, Schneppenheim R, Siebert R, Frühwald MC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301744" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301625" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Retinoblastoma</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Retinoblastoma<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lohmann DR, Gallie BL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24761742" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">DICER1</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">DICER1</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Doros L, Schultz KA, Stewart DR, Bauer AJ, Williams G, Rossi CT, Carr A, Yang J, Dehner LP, Messinger Y, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301715" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Paraganglioma-Pheochromocytoma Syndromes</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Paraganglioma-Pheochromocytoma Syndromes<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Else T, Greenberg S, Fishbein L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301782" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301782" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042b4639a66ee2bac72624">ALK-Related Neuroblastic Tumor Susceptibility - GeneReviews®</a><div class="ralinkpop offscreen_noflow">ALK-Related Neuroblastic Tumor Susceptibility - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:38:46-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8DB332E041BA9100000000070D02C7&amp;ncbi_session=CE8DB332E042B461_1805SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK24599%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK24599&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK24599/&amp;ncbi_pagename=ALK-Related Neuroblastic Tumor Susceptibility - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DB332E042B461_1805SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>